Loading...
$1.1M
Awarded Sep 10, 2026
Competition
FULL AND OPEN COMPETITION
Offers
1
Set-Aside
None
Solicitation Type
SUBJECT TO MULTIPLE AWARD FAIR OPPORTUNITY
Program
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT
Performance Timeline
Start
Sep 14, 2026
Estimated start: Sep 13, 2027
Contract: 75N91026F00001
UEI
GY8NMUZQXVS7
Parent Company
UNIVERSITY OF OKLAHOMA
Capabilities & Certifications
Headquarters Location
Congressional District: 05
Current Obligation
$1,147,754
Base + Exercised Options
$1,147,754
Total Ceiling Value
$1,147,754
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
Description
TRIPLE NEGATIVE BREAST CANCER VACCINES
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Place of Performance
Congressional District: 05
Awarding Agency
Top-tier Agency
National Institutes of Health
Sub-tier Agency
NIH NCI
Office
Funding Agency
Top-tier Agency
National Institutes of Health
Sub-tier Agency
NIH NCI
Office
Contract Vehicle
75N91024D00005
IDCDepartment of Health and Human Services
Award Type: MULTIPLE AWARD